Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so participants may form their own judgments, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement, nor a recommendation, on the part of Serono Symposia International Foundation. All presentations solely represent the independent views of the presenters/authors.
The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non- EMEA/FDA approved (off-label) uses of drugs:
Maria Jesus Arévalo: Declared no potential conflict of interest.
Georgina Arrambide: Declared receipt of a McDonald Fellowship, Multiple Sclerosis International Federation.
Manuel Comabella: Declared no potential conflict of interest.
Giancarlo Comi: Declared receipt of honoraria or consultation fees from Bayer-Schering, Teva Pharmaceutical Industries Ltd., Merck Serono, Sanofi Aventis, Novartis, Biogen Dompè.
Carme Costa: Declared no potential conflict of interest.
Herena Eixharch: Declared no potential conflict of interest.
Monica Falautano: Declared no potential conflict of interest.
Oscar Fernández: Declared no potential conflict of interest.
Nicolàs Fissolo: Declared no potential conflict of interest.
Angelo Ghezzi: Declared receipt of honoraria or consultation fees from Actelion, Novartis and Dompé.
Eva Havrdovà: Declared receipt honoraria or consultation fees from Teva, Biogen Idec, Merck Serono, Genzyme. She declared also to be a member of Biogen Idec and Genzyme advisory boards for clinical trials. She declared also benefits from a relationship with a commercial enterprise as investigator in clinical trial Biogen Idec, Merck Serono, Genzyme and GSK.
Alejandro Horga: Declared no potential conflict of interest.
Rosalía Horno: Declared no potential conflict of interest.
Ester Moral: Declared no potential conflict of interest.
Carlos Nos: Declared receipt of honorarium for giving expert advice to BaroFold.
Lluis Ramió i Torrentá: Declared receipt of grants and contracts and honoraria or consultation fees from Biogen, Bayer-Schering, Teva, Sanofi-Aventis, Merck Serono.
Marta Renom Guiteras: Declared no potential conflict of interest.
Jordi Rio: Declared no potential conflict of interest.
Gemma Rodríguez: Declared no potential conflict of interest.
Alex Rovira: Declared no potential conflict of interest.
Carme Santoyo: Declared no potential conflict of interest.
Jaume Sastre-Garriga: Declared to be member of a Biogen advisory board, board of directors or other similar groups. He declared also participation in a Biogen, Bayer-Schering, Merck Serono and Sanofi-Aventis sponsored speaker’s bureau.
Alan J. Thompson: Declared receipt of fees from Eisai London Research Labs (Advisory Board member), fees and support for travel from Novartis Pharma (PPMS steering group member); honorarium and support for travel from Sanofi-Aventis and Serono Symposia International Foundation (invited lectures); NIHR-Senior Investigator. He declared to be member of London Research Labs at UCL Advisory Board; Trustee Patrick Berthoud Trust; Trustee National Hospital Development Foundation; chairman MSIF International Medical and Scientific Board. He declared also benefits from a relationship with a commercial enterprise: Honorarium as Editor-in-Chief Multiple Sclerosis (Sage publications); free subscription as member Editorial Board for Lancet Neurology; member Editorial Advisory Board for Current Medical Literature - Multiple Sclerosis.
Mar Tintoré: Declared receipt of grants and contracts and honoraria or consultation fees from Bayer-Schering, Biogen-Idec, Merck Serono, Teva, Sanofi-Aventis and Novartis.
Carmen Tur: Declared no potential conflict of interest.
The following faculty have provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of October 27, 2009.
Xavier Montalban
Lucia Romero
Carmen Infante
